Acorda Therapeutics, Inc. short interest in 2023
In 2023, Acorda Therapeutics, Inc.'s disclosed short interest ran from 1.78% of shares outstanding on 13 Jan 2023 to 0.64% on 29 Dec 2023, a change of -1.14 percentage points. The year's high was 1.78% on 13 Jan 2023 and its low 0.52% on 31 Mar 2023, averaging 1.04% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.77 days on 30 Nov 2023. Full history: Acorda Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024
2023 in figures
- Start of year
- 1.78% (13 Jan 2023)
- End of year
- 0.64% (29 Dec 2023)
- Change
- -1.14 pp
- High
- 1.78% (13 Jan 2023)
- Low
- 0.52% (31 Mar 2023)
- Average
- 1.04%
- Highest days to cover
- 6.77 (30 Nov 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 1.78% | 1.34 | |
| 31 Jan 2023 | 1.37% | 1.09 | |
| 15 Feb 2023 | 1.01% | 1.72 | |
| 28 Feb 2023 | 1.14% | 4.02 | |
| 15 Mar 2023 | 1.05% | 1.02 | results (8-K), 10-K filed |
| 31 Mar 2023 | 0.52% | 1.30 | |
| 14 Apr 2023 | 0.82% | 3.92 | |
| 28 Apr 2023 | 0.82% | 4.92 | |
| 15 May 2023 | 1.63% | 1.00 | 10-Q filed, results (8-K) |
| 31 May 2023 | 0.95% | 1.00 | |
| 15 Aug 2023 | 1.04% | 1.19 | results (8-K), 10-Q filed |
| 31 Aug 2023 | 0.55% | 1.00 | |
| 15 Sep 2023 | 1.07% | 1.35 | |
| 29 Sep 2023 | 0.78% | 1.56 | |
| 13 Oct 2023 | 1.17% | 1.02 | |
| 31 Oct 2023 | 1.06% | 2.70 | |
| 15 Nov 2023 | 1.09% | 4.16 | results (8-K), 10-Q filed |
| 30 Nov 2023 | 1.34% | 6.77 | |
| 15 Dec 2023 | 1.05% | 1.75 | |
| 29 Dec 2023 | 0.64% | 1.62 |
See also: Acorda Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.